Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
This study enrolls adults who have had a positive test for COVID-19. The purpose of this study is to learn more about how the infection works, including how the virus evolves and how a person infected with COVID-19's body responds. Knowing more about the virus at a cellular level will help scientists develop better treatments for this devastating disease. Read More
-Positive for COVID-19
-We will restrict asymptomatic enrollees to a maximum of 20% (100) participants. Once that number is achieved, symptoms of COVID-19 will be required for inclusion in to the study.
This study enrolls children ages 5-17 with asthma. The purpose of this research study is to find out if a breathing test called FeNO changes how doctors decide to treat your asthma. The FeNO test measures the amount of nitric oxide in the air you slowly breath out of your lungs and is a test for inflammation in the lungs. The FeNO test can also help doctors determine how well your asthma medications are suppressing inflammation in the lungs. Read More
Children ages 5-17.
Diagnosis of asthma.
Patients of the UBMD Pediatrics Allergy/Immunology clinic.
This study enrolls premature babies with apnea in the NICU who have been treated with caffeine medication. The purpose of this study is to find out if continuing caffeine will help babies be discharged sooner. Read More
Children- babies born prematurely between 29-33 weeks gestation.
Have been diagnosed with apnea.
Have been treated with caffeine.
Are currently in the Neonatal Intensive Care Unit (NICU).
This registry study enrolls people who have had a blood clot in a large blood vessel in their chest that is interfering with heart and lung blood flow. It enrolls people whose doctor has then decided to use a clot-dissolving drug in combination with a commercially-available device, called the EkoSonic® Endovascular System (EKOS). The purpose of this Registry is to understand how doctors are currently treating lung artery clots with clot-dissolving drugs and EKOS. Read More
Adults ages 18+.
Have a blood clot in one or both of the large blood vessels in your chest (lung arteries) that is interfering with blood flow through your heart
Your doctor has decided to use a clot-dissolving drug (thrombolytic drug) in combination with the EkoSonic® Endovascular System (EKOS).
We are looking for children age 7-16 years old with asthma and their parents for a research study. The purpose of this study is to find out if children and their parents have different or similar opinions on how much their child’s asthma affects their everyday life. Read More
This study enrolls infants who are admitted to Oishei Children's hospital's Pediatric Intensive Care Unit (PICU) with bronchiolitis. The purpose of this study is to see how a medication for the condition compares with usual care. Read More
Children (infants) less than 8 months of age.
Admitted to PICU with bronchiolitis.